Akebia Therapeutics Inc
AKBA3.720USD
0.000
Horário de mercado （ET）Cotações atrasadas em 15 min
973.32MValor de mercado
PerdaP/L TTM
Mais detalhes de Akebia Therapeutics Inc Empresa
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Informações da empresa
Código da empresaAKBA
Nome da EmpresaAkebia Therapeutics Inc
Data de listagemMar 20, 2014
CEOMr. John P. Butler
Número de funcionários181
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 20
Endereço245 First Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Telefone16178712098
Sitehttps://akebia.com/
Código da empresaAKBA
Data de listagemMar 20, 2014
CEOMr. John P. Butler
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 31 de jul
Atualizado em: qui, 31 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
Tipos de investidores
Investidores
Proporção
Investment Advisor
13.32%
Investment Advisor/Hedge Fund
10.58%
Hedge Fund
9.31%
Individual Investor
3.61%
Research Firm
2.48%
Private Equity
2.19%
Bank and Trust
0.14%
Pension Fund
0.04%
Insurance Company
0.03%
Other
58.30%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
281
109.59M
41.73%
+26.45M
2025Q1
280
111.54M
42.50%
+30.68M
2024Q4
258
78.54M
36.08%
+7.41M
2024Q3
257
64.16M
30.51%
-2.18M
2024Q2
248
61.31M
29.27%
-7.52M
2024Q1
290
61.37M
29.36%
-12.30M
2023Q4
289
58.79M
31.24%
-20.79M
2023Q3
300
57.28M
30.45%
-25.18M
2023Q2
308
56.18M
30.22%
-26.52M
2023Q1
315
56.14M
30.23%
-26.40M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
13.97M
5.32%
+133.23K
+0.96%
Mar 31, 2025
The Vanguard Group, Inc.
12.69M
4.83%
+1.80M
+16.55%
Mar 31, 2025
State Street Global Advisors (US)
6.81M
2.59%
+501.11K
+7.95%
Mar 31, 2025
Alerce Investment Management, L.P.
5.75M
2.19%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.19%
+5.75M
--
Dec 31, 2024
Geode Capital Management, L.L.C.
5.03M
1.92%
+235.65K
+4.91%
Mar 31, 2025
Great Point Partners, LLC
4.97M
1.89%
+4.97M
--
Mar 31, 2025
Renaissance Technologies LLC
4.01M
1.53%
+182.30K
+4.77%
Mar 31, 2025
Citadel Advisors LLC
3.65M
1.39%
+2.26M
+163.86%
Mar 31, 2025
Franklin Advisers, Inc.
2.67M
1.02%
+2.50M
+1495.36%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
0.65%
Invesco NASDAQ Future Gen 200 ETF
0.54%
Federated Hermes MDT Small Cap Core ETF
0.27%
SPDR S&P Biotech ETF
0.23%
iShares Micro-Cap ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.13%
iShares Russell 2000 Value ETF
0.06%
Global X Russell 2000 ETF
0.04%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção0.65%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.54%
Federated Hermes MDT Small Cap Core ETF
Proporção0.27%
SPDR S&P Biotech ETF
Proporção0.23%
iShares Micro-Cap ETF
Proporção0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.13%
Fidelity Enhanced Small Cap ETF
Proporção0.13%
iShares Russell 2000 Value ETF
Proporção0.06%
Global X Russell 2000 ETF
Proporção0.04%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
